Evidence map›Paper›PMID 32724283›Full record

ArticleActa clinica Croatica2020

THE IMPACT OF POSITIVE ANTI-HBC MARKER ON PERMANENT DEFERRAL OF VOLUNTARY BLOOD DONORS IN EASTERN CROATIA AND ESTIMATION OF OCCULT HEPATITIS B VIRUS INFECTION RATE.

Marko Samardžija, Domagoj Drenjančević, Manuela Miletić, Blaženka Slavulj, Irena Jukić, Lada Zibar, Silvio Mihaljević, Marina Ferenac Kiš, Marina Samardžija

Open access · diamondAbstract read
In one paragraph

Article in Acta clinica Croatica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Marko Samardžija1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Domagoj Drenjančević1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Manuela Miletić1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Blaženka Slavulj1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Irena Jukić1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Lada Zibar1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Silvio Mihaljević1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Marina Ferenac Kiš1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Marina Samardžija1Nord-Trøndelag Hospital Trust, Namsos Hospital, Department of Internal Medicine, Namsos, Norway; 2Osijek University Hospital Centre, Department of Transfusion Medicine, Osijek, Croatia; 3Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 5Merkur University Hospital, Department of Internal Medicine, Zagreb, Croatia; 6Osijek University Hospital Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Osijek, Croatia.
Namsos Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently an increase has been reported in the number of HBV transmissions from anti-HBc positive blood donors that were repeatedly negative in HBsAg and nucleic acid testing using the most sensitive tests available. The aim of the study was to show the effect of anti-HBc antibody testing performed in 2006 on permanent deferral of voluntary blood donors (VBDs), and to estimate occult hepatitis B infection (OBI) rate in this population after the introduction of mandatory molecular testing in the 2013-2016 period. More than 30,000 blood donations collected during the 2005-2007 period and more than 14,000 VBDs having donated blood during the 2013-2016 period after the introduction of molecular testing from eastern Croatia were included in the study. Serologic testing was performed with HBsAg assay throughout the study period, and anti-HBc assay was only performed in 2006. As part of the confirmatory algorithm testing, all HBsAg positive and unclear results were tested with molecular tests. Anti-HBc prevalence among VBDs in 2006 was 1.5%, with a rate of 1:197, whereas HBsAg prevalence was stable from 2005 to 2007 (0.04%, 0.1% and 0.1%, respectively). The calculated OBI rate from 2013 to 2016 was 1:30,250. Ten of 161 (12.4%) VBDs had serologic anti-HBc-only pattern. Anti-HBc testing in 2006 resulted in statistically more deferrals of VBDs compared to 2005 and 2007, and to the rest of Republic of Croatia. The strategy of universal anti-HBc testing of VBDs in addition to the existing HBsAg and molecular screening could be an additional measure to prevent HBV transmission by blood and blood components.

Indexed as

Blood DonorsHepatitis BHepatitis B virusCroatiaDNA, ViralHumansDNA, ViralBlood donorsCroatiaHepatitis BHepatitis B surface antigenHepatitis B virus

Identifiers

PMID32724283
PMCPMC7382879
OpenAlexW3046403259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.